Treatment of collagen-induced arthritis by Natura-α via regulation of Th-1/Th-17 responses

European Journal of Immunology

Volumn 40, Issue 2, 2010, Pages 460-469

  Glatigny, Simon ^a,b   Blaton, Marie Agnès ^a,b   Mencher, Simon K ^c   Mistou, Sylvie ^a,b   Lucas, Bruno ^a,b   Fournier, Catherine ^a,b   Wang, Long G ^c   Chiocchia, Gilles ^a,b,d  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Natrogen Therapeutics International Inc   (United States)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Arthritis; Cytokine; Th 1; Th 17

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CD28 ANTIGEN; CD3 ANTIGEN; COLLAGEN TYPE 2; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 4; NATURA ALPHA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPLEEN; TH1 CELL; TH17 CELL;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; CELL DIFFERENTIATION; COLLAGEN TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGLOBULIN G; INDOLES; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; KINETICS; MALE; MICE; MICE, INBRED DBA; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TIME FACTORS;

EID: 75149167993     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939566     Document Type: Article

References (44)

1. Kim, W. U., Cho, M. L., Jung, Y. O., Min, S. Y., Park, S. W., Min, D. J., Yoon, J. H. and Kim, H. Y., Type II collagen autoimmunity in rheumatoid arthritis. Am. J. Med. Sci. 2004. 327: 202-211.
2. Cathcart, E. S., Hayes, K. C., Gonnerman, W. A., Lazzari, A. A. and Franzblau, C., Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab Invest. 1986. 54: 26-31.
3. Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A. and Mosedale, B., Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980. 283: 666-668.
4. Holmdahl, R., Jansson, L., Gullberg, D., Rubin, K., Forsberg, P. O. and Klareskog, L., Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin. Exp. Immunol. 1985. 62: 639-646.
5. Holmdahl, R., Jansson, L., Larsson, E., Rubin, K. and Klareskog, L., Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum. 1986. 29: 106-113.
6. Boissier, M. C., Chiocchia, G. and Fournier, C., [Clinical and experimental anticollagen autoimmunity]. C. R. Seances Soc. Biol. Fil. 1989. 183: 293-306.
7. Chiocchia, G., Manoury, B., Boissier, M. C. and Fournier, C., T cell-targeted immunotherapy in murine collagen-induced arthritis. Clin. Exp. Rheumatol. 1993. 11: S15-S17.
8. Doncarli, A., Chiocchia, G., Stasiuk, L. M., Herbage, D., Boutillon, M. M., Fournier, C. and Abehsira-Amar, O., A recurrent valpha17/vbeta10 TCRexpressing T cell clone is involved in the pathogenicity of collageninduced arthritis in DBA/1 mice. Eur. J. Immunol. 1999. 29: 3636-3642.
9. Marinova-Mutafchieva, L., Williams, R. O., Mason, L. J., Mauri, C., Feldmann, M. and Maini, R. N., Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 1997. 107: 507-512.
10. Mauri, C., Williams, R. O., Walmsley, M. and Feldmann, M., Relationship between Th-1/Th-2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 1996. 26: 1511-1518.
11. Bessis, N., Chiocchia, G., Kollias, G., Minty, A., Fournier, C., Fradelizi, D. and Boissier, M. C., Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin. Exp. Immunol. 1998. 111: 391-396.
12. Germann, T., Szeliga, J., Hess, H., Storkel, S., Podlaski, F. J., Gately, M. K., Schmitt, E. and Rude, E., Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA 1995. 92: 4823-4827.
13. Leung, B. P., McInnes, I. B., Esfandiari, E., Wei, X. Q. and Liew, F. Y., Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J. Immunol. 2000. 164: 6495-6502.
14. Guery, L., Batteux, F., Bessis, N., Breban, M., Boissier, M. C., Fournier, C. and Chiocchia, G., Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur. J. Immunol. 2000. 30: 308-315.
15. Guery, L., Chiocchia, G., Batteux, F., Boissier, M. C. and Fournier, C., Collagen II-pulsed antigen-presenting cells genetically modified to secrete IL-4 down-regulate collagen-induced arthritis. Gene Ther. 2001. 8: 1855-1862.
16. Johansson, A. C., Hansson, A. S., Nandakumar, K. S., Backlund, J. and Holmdahl, R., IL-10-deficient B10.Q mice develop more severe collageninduced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J. Immunol. 2001. 167: 3505-3512.
17. Boissier, M. C., Chiocchia, G., Bessis, N., Hajnal, J., Garotta, G., Nicoletti, F. and Fournier, C., Biphasic effect of interferon-gamma inmurine collageninduced arthritis. Eur. J. Immunol. 1995. 25: 1184-1190.
18. Manoury-Schwartz, B., Chiocchia, G., Bessis, N., Abehsira-Amar, O., Batteux, F., Muller, S., Huang, S. et al., High susceptibility to collageninduced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 1997. 158: 5501-5506.
19. Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A. and Matthys, P., Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 1997. 158: 5507-5513.
20. Matthys, P., Vermeire, K., Mitera, T., Heremans, H., Huang, S. and Billiau, A., Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur. J. Immunol. 1998. 28: 2143-2151.
21. Plater-Zyberk, C., Joosten, L. A., Helsen, M. M., Sattonnet-Roche, P., Siegfried, C., Alouani, S., van De Loo, F. A. et al., Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 2001. 108: 1825-1832.
22. McIntyre, K. W., Shuster, D. J., Gillooly, K. M., Warrier, R. R., Connaughton, S. E., Hall, L. B., Arp, L. H. et al., Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur. J. Immunol. 1996. 26: 2933-2938.
23. Wei, X. Q., Leung, B. P., Arthur, H. M., McInnes, I. B. and Liew, F. Y., Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 2001. 166: 517-521.
24. Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F. et al., Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000. 13: 715-725.
25. Gottenberg, J. E. and Chiocchia, G., Dendritic cells and interferonmediated autoimmunity. Biochimie 2007. 89: 856-871.
26. Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H. et al., Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 2006. 116: 2633-2642.
27. Leder, C., Ortler, S., Seggewiss, R., Einsele, H. andWiendl, H., Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp. Hematol. 2007. 35: 1266-1271.
28. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. and Kuchroo, V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH-17 and regulatory T cells. Nature 2006. 441: 235-238.
29. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. and Stockinger, B., TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006. 24: 179-189.
30. Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D. et al., Transforming growth factorbeta induces development of the T(H)17 lineage. Nature 2006. 441: 231-234.
31. Kimura, A., Naka, T. and Kishimoto, T., IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci USA 2007. 104: 12099-12104.
32. Nishihara, M., Ogura, H., Ueda, N., Tsuruoka, M., Kitabayashi, C., Tsuji, F., Aono, H. et al., IL-6-gp130-STAT3 in T cells directs the development of IL-171Th with a minimum effect on that of Treg in the steady state. Int. Immunol. 2007. 19: 695-702.
33. Ogura, H., Murakami, M., Okuyama, Y., Tsuruoka, M., Kitabayashi, C., Kanamoto, M., Nishihara, M. et al., Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008. 29: 628-636.
34. + regulatory T cells. Proc. Natl. Acad. Sci. USA 2008.
35. Galdiero, M., Vitiello, M., D'Isanto, M., Raieta, K. and Galdiero, E., STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6. Cytokine 2006. 36: 218-228.
36. Murray, P. J., STAT3-mediated anti-inflammatory signalling. Biochem. Soc. Trans. 2006. 34: 1028-1031.
37. Atreya, R., Atreya, I. and Neurath, M. F., Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 2006. 1072: 98-113.
38. Ishihara, K. and Hirano, T., IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002. 13: 357-368.
39. Liu, H. and Pope, R. M., The role of apoptosis in rheumatoid arthritis. Curr. Opin. Pharmacol. 2003. 3: 317-322.
40. Mitsuyama, K., Sata, M. and Rose-John, S., Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 2006. 17: 451-461.
41. Suzuki, A., Hanada, T., Mitsuyama, K., Yoshida, T., Kamizono, S., Hoshino, T., Kubo, M. et al., CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 2001. 193: 471-481.
42. Zhang, W., Chen, X., Shi, S., Wei, R., Wang, J., Yamanaka, N. and Hong, Q., Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril. Nephrol. Dial. Transplant. 2005. 20: 892-901.
43. Chiocchia, G., Boissier, M. C. and Fournier, C., Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur. J. Immunol. 1991. 21: 2899-2905.
44. Tourneur, L., Damotte, D., Marion, S., Mistou, S. and Chiocchia, G., IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. Eur. J. Immunol. 2002. 32: 1292-1299.